From the Journals

In CRC patients, chemo yields more toxicities in women than in men

Publish date: June 1, 2018

 

FROM JAMA ONCOLOGY


Dr. Cristina had no conflicts of interest to disclose. Coauthors reported disclosures related to Amgen, Bayer, Boehringer, Bristol-Myers Squibb, Celgene, Ipsen, Lilly, Merck, Merck KgA, Novartis, Pfizer, Roche, Sanofi, Servier, and Shire.

SOURCE: Cristina V et al. JAMA Oncol. 2018 May 24. doi: 10.1001/jamaoncol.2018.1080.

Pages

Recommended Reading

Study eyes liver transplantation after Region 5 UNOS downstaging
MDedge Hematology and Oncology
Advanced adenoma on colonoscopy linked to increased colorectal cancer incidence
MDedge Hematology and Oncology
Is cancer immunotherapy more effective in men than women?
MDedge Hematology and Oncology
Intraperitoneal chemo missed main endpoint, yet may benefit gastric cancer
MDedge Hematology and Oncology
Breath test may detect esophagogastric cancer
MDedge Hematology and Oncology
Blood type A linked to more-severe diarrhea
MDedge Hematology and Oncology
CRC recurrence surveillance studies: No benefit to high-intensity strategy
MDedge Hematology and Oncology
FDA approves Doptelet for liver disease patients undergoing procedures
MDedge Hematology and Oncology
New ‘immune checkpoint’ vaccine shows promise in treating colorectal cancer
MDedge Hematology and Oncology
MDedge Daily News: Keeping patients summer safe
MDedge Hematology and Oncology